Research
Hormonal
Incretin-based therapy did not increase the risk of hypoglycaemia or pancreatitis.
Clinicians can consider incretin-based therapies as safe options for managing obesity and hypertension without increasing hypoglycaemia or pancreatitis risk.
StrongSupportsmedium confidence
Incretin-based therapy did not increase the risk of hypoglycaemia (RR 1.05, 95% CI 0.83-1.33) or pancreatitis (RR 0.84, 95% CI 0.61-1.15).
Why this rating
Based on a systematic review and meta-analysis of 85 RCTs.
Source
Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis
Christian Basile et al. · European Journal of Preventive Cardiology · 2025
DOI 10.1093/eurjpc/zwaf560
Meta-analysisCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →